Cookies, the most globally recognised cannabis brand, is entering global medical markets with a full extract portfolio through a strategic partnership with SOMAÍ, a leading EU-GMP-certified vertically integrated Multi-Country Operator (MCO).
This collaboration marks a new era for full-branded portfolios of medicinal cannabis products with Cookies’ signature terpene and flavonoid profiles, the foundation of its world-renowned flower reputation, are now refined, standardised, and transformed into pharmaceutical-grade extracts under SOMAÍ’s precise EU-GMP manufacturing standards.
Defining Taste — From Culture to Science
Cookies has long been celebrated for its iconic and evolving flower genetics — a brand built on flavour, experience, and culture. SOMAÍ now bridges that legacy with pharmaceutical innovation, transforming Cookies’ distinctive terpene and flavonoid profiles into highly standardised medical extracts.
These carefully formulated oral and inhalation products preserve the full sensory experience of Cookies’ strains— its recognisable aroma, flavour, and entourage profile — while meeting the highest standards of safety, stability, and purity.
“At SOMAÍ, we believe that taste isn’t just an experience — it’s a part of how patients connect with their medicine,” said Michael Sassano, Founder and Interim CEO of SOMAÍ. “Bringing Cookies’ iconic terpene blends into the medical space allows us to merge culture with compliance and deliver products that patients trust, enjoy, and truly benefit from.”
“SOMAÍ brings a level of pharmaceutical rigour and global execution that is rare in this industry. Their ability to translate culture and cultivar nuance into standardised, medical-grade formulations is unmatched. We are proud to partner with a company that honours Cookies’ legacy while elevating it into regulated markets worldwide,” said Parker Berling, President, Cookies.
By maintaining consistency in terpene and flavonoid blends, SOMAÍ and Cookies are setting a new global benchmark for medicinal cannabis — where authentic terpene formulations meet pharmaceutical precision.
A Global Medical Partnership
Under this collaboration, SOMAÍ opens the doors for different demographics to experience iconic Cookie’s products through oral drops, inhalation devices, and oral gums.
SOMAÍ will manufacture, distribute, and commercialise Cookies-branded cannabis extracts for medical use across regulated markets worldwide.
Cookies will be the first major brand to have a full global portfolio of flower and extract products.
Their EU-GMP-certified portfolios combine Cookies’ legendary genetic foundation with SOMAÍ’s pharmaceutical rigour, enabling physicians and patients to access cannabis-based medicines that are clinically standardised and sensorially recognisable.
